Showing results (121-130 of 130) with videos related to
Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
The Journal of Pharmacology and Experimental Therapeutics|May 30, 2015
Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional CharacterizationWei-Peng Wang, Pui Yan Ho, Qiu-Xia Chen, et al.Clinical Chemistry|January 4, 2021
Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response MonitoringJared C Nesvet, Katie A Antilla, Danielle S Pancirer, et al.Journal of Hematology & Oncology|November 8, 2018
Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumorsCathy Zhou, Zilong Yuan, Weijie Ma, et al.Clinical Lung Cancer|April 4, 2015
Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platformDavid R Gandara, Philip C Mack, Carol Bult, et al.Nature Communications|September 1, 2023
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trialArta M Monjazeb, Megan E Daly, Guillaume Luxardi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung CancerDaniel Morgensztern, Neal Ready, Melissa L Johnson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung CancerJulia K Rotow, Philippe Gui, Wei Wu, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A Thompson, Bryan J Schneider, Julie Brahmer, et al.Nature Medicine|March 28, 2026
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trialByoung Chul Cho, Rama Balaraman, Hua-Jun Chen, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 13, 2024
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024John A Thompson, Bryan J Schneider, Julie Brahmer, et al.Pageof 13